ProGnosis Biotech S.A
ProGnosis Biotech is an innovative Biotechnology Company, specialized in developing next-generation immuno-assays for the food/feed & clinical diagnostics industries.
ProGnosis Biotech is an innovative Biotechnology Company, specialized in developing and manufacturing next-generation immuno-assays for the food/feed & clinical diagnostics industries.
Based in Larissa, Greece, and having offices in Thessaloniki, Madrid, and Beijing, ProGnosis Biotech is an export-oriented enterprise which through a large network of distributors, exports ELISA kits and Lateral-flow tests to more than 40 countries worldwide.
In order to consistently provide top-quality products, our company participates on a monthly basis in Proficiency Tests in the UK, France, Germany, Italy, and the US. Additionally, ProGnosis Biotech offers validated products from the most highly esteemed organizations worldwide, and all the R&D and production procedures are certified with ISO 9001.
“Accuracy Through Innovation”
Our mission is to provide innovative, accurate and simple solutions to the challenges presented in the food safety & clinical diagnostics industries. Our vision is to achieve a leading role in the diagnostics field by promoting consumers’ wellbeing based on high-quality standards
Product News
View All Product News
Products
Bio-Shield 2019-nCoV IgG (C1148/C1196)
Clinical
Bio-Shield 2019-nCoV IgG, is a semi-quantitative ELISA test for the determination of IgG antibodies against SARS-CoV-2 in human serum or plasma (Heparin, EDTA or Citrate) specimens
Bio-Shield 2019-nCoV IgM (C1248/C1296)
Clinical
Bio-Shield 2019-nCoV IgM, is a semi-quantitative ELISA test for the determination of IgM antibodies against SARS-CoV-2 in human serum or plasma (Heparin, EDTA or Citrate) specimens
Bio-Shield 2019-nCoV Total Immunoglobulins (C1348/C1396)
Clinical
Bio-Shield 2019-nCoV Total Immunoglobulins, is a semi-quantitative ELISA test for the determination of IgA, IgM, IgG antibodies against SARS-CoV-2 in human serum or plasma (Heparin, EDTA or Citrate) specimens.
Rapid test 2019-nCoV Total Immunoglobulins (V1210/V1230)
Clinical
Rapid test 2019-nCoV Total is a qualitative Lateral Flow test for the determination of IgA, IgM, and IgG antibodies against SARS-CoV-2 in human serum, plasma, or whole blood specimens.Microbiology Product Areas
Assay Development | ||
| Contract Development Manufacturing Organisation | Show all suppliers | |
ClinicalNOTE: The products listed in this section may not be approved for clinical diagnostic use in your jurisdiction. You must assume these products are unregulated and therefore cannot be used for routine testing and reporting of results unless otherwise stated. | ||
| Antibodies | Show all suppliers | |
| ELISA | Show all suppliers | |
| SARS-CoV-2 | Show all suppliers | |
Food & Beverage | ||
| Aflatoxins | Show all suppliers | |
| Lateral Flow Assays | Show all suppliers | |
| Mycotoxins | Show all suppliers | |